NKGen Biotech, Inc.
NKGNDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SNK01 | Phase 2 | Moderate Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NKGen Biotech, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in NKGen Biotech, Inc.'s (NKGN) pipeline across Phase 2. Its lead program is SNK01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NKGen Biotech, Inc.'s next FDA catalyst?→
NKGen Biotech, Inc.'s (NKGN) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NKGN biotech catalysts?→
Add NKGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NKGen Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.